Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Renal Cell 27Neoplasms 14Neoplasm Metastasis 14Glioblastoma 14Prostatic Neoplasms 13Lymphoma, Mantle-Cell 11Breast Neoplasms 11Brain Neoplasms 11Sarcoma 10Lymphoma, Non-Hodgkin 10Kidney Neoplasms 10Endometrial Neoplasms 10Melanoma 9Gliosarcoma 8Multiple Myeloma 7Glioma 7Ovarian Neoplasms 6Carcinoma, Hepatocellular 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Oligodendroglioma 5Lymphoma, Follicular 5Lymphoma 5Hodgkin Disease 5Central Nervous System Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Astrocytoma 5Waldenstrom Macroglobulinemia 4Uterine Cervical Neoplasms 4Unspecified Adult Solid Tumor, Protocol Specific 4Rhabdomyosarcoma 4

Interventions

Surveys and Questionnaires 5pazopanib 3Erlotinib Hydrochloride 3Cetuximab 3Vorinostat 2Oxaliplatin 2Bevacizumab 2Azacitidine 2temsirolimus 1satraplatin 1ridaforolimus 1ixazomib 1X-Rays 1Videotape Recording 1Valproic Acid 1Trastuzumab 1Sugars 1Sorafenib 1Platinum 1Pemetrexed 1Magnetic Resonance Spectroscopy 1Leucovorin 1Lenalidomide 1Lapatinib 1LY 2275796 1Injections, Subcutaneous 1Fluorouracil 1Everolimus 1Curcumin 1Crizotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Cancers × temsirolimus × Clear all
NCT00877773 2016-08-25

Phosphatidylinositol 3 Kinase and Mammalian Target of Rapamycin (PI3K-mTOR) in Advanced Cancer Patients

M.D. Anderson Cancer Center

Phase 1/2 Terminated
44 enrolled 5 charts

Advanced Cancers

Data powered by HemOnc (CC BY 4.0) Colophon âš¡